No abstract

No abstract

No abstract

Background : Neoadjuvant chemotherapy has become a standard therapy for patients with locally advanced breast cancer. Recently, new regimens of breast cancer chemotherapy containing taxanges further improve survival compared with standard chemotherapy regimens, but taxanes are toxic, expensive,and might benefit only a few patients. However, predictive factors in breast cancer treated with neoadjuvant chemotherapy differ from those of early breast cancer. The purpose of this study was to identify the clinical significance of potential predictive factors in breast cancer patients treated by neoadjuvant chemotherapy.Methods : A total of 112 stage II and III breast cancer patients received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study. We examined the clinical and biological factors by immunohistochemistry. We analyzed clinical outcome and their correlation with clinicopathologic parameters.Results : A total of 112 patients with a median age of 45.9 were evaluated in this study. The overall clinical response rate(RR) was 80(71.5%) including 5(4.5%) complete response and 75(67.0%) partial response.Consequently, 12 (10.6%) patients achieved a pCR. Among the traditional clinicopathologic parameters(age, stage, histologic grade, ER, PR, c-erbB2, p53 and Ki-67) investigated, none of the marker was correlated with response rate(RR). However, pCR was correlated with initial tumor stage(p=.004), triple negative(p=.002), p53(p=.011), .Conclusions : Several molecular markers provided useful predictive information in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Triple negative phenotype, p53 high expression and Ki-67 high expression was associated with a higher pCR to neoadjuvant docetaxel/doxorubicin chemotherapy.

No abstract